BACKGROUND: Protein disulfide isomerase (PDI) is required for thrombus formation. We previously demonstrated that glycosylated quercetin flavonoids such as isoquercetin inhibit PDI activity and thrombus formation in animal models, but whether extracellular PDI represents a viable anticoagulant target in humans and how its inhibition affects blood coagulation remain unknown. METHODS: We evaluated effects of oral administration of isoquercetin on platelet-dependent thrombin generation in healthy subjects and patients with persistently elevated anti-phospholipid antibodies. RESULTS: Following oral administration of 1,000 mg isoquercetin to healthy adults, the measured peak plasma quercetin concentration (9.2 μM) exceeded its IC50 for inhibition of PDI by isoquercetin in vitro (2.5 ± 0.4 μM). Platelet-dependent thrombin generation decreased by 51% in the healthy volunteers compared with baseline (P = 0.0004) and by 64% in the anti-phospholipid antibody cohort (P = 0.015) following isoquercetin ingestion. To understand how PDI affects thrombin generation, we evaluated substrates of PDI identified using an unbiased mechanistic-based substrate trapping approach. These studies identified platelet factor V as a PDI substrate. Isoquercetin blocked both platelet factor Va and thrombin generation with an IC50 of ~5 μM. Inhibition of PDI by isoquercetin ingestion resulted in a 53% decrease in the generation of platelet factor Va (P = 0.001). Isoquercetin-mediated inhibition was reversed with addition of exogenous factor Va. CONCLUSION: These studies show that oral administration of isoquercetin inhibits PDI activity in plasma and diminishes platelet-dependent thrombin generation predominantly by blocking the generation of platelet factor Va. These pharmacodynamic and mechanistic observations represent an important step in the development of a novel class of antithrombotic agents targeting PDI. TRIAL REGISTRATION: Clinicaltrials.gov (NCT01722669) FUNDING: National Heart, Lung, and Blood Institute (U54 HL112302) and Quercegen Pharma.
BACKGROUND:Protein disulfide isomerase (PDI) is required for thrombus formation. We previously demonstrated that glycosylated quercetin flavonoids such as isoquercetin inhibit PDI activity and thrombus formation in animal models, but whether extracellular PDI represents a viable anticoagulant target in humans and how its inhibition affects blood coagulation remain unknown. METHODS: We evaluated effects of oral administration of isoquercetin on platelet-dependent thrombin generation in healthy subjects and patients with persistently elevated anti-phospholipid antibodies. RESULTS: Following oral administration of 1,000 mg isoquercetin to healthy adults, the measured peak plasma quercetin concentration (9.2 μM) exceeded its IC50 for inhibition of PDI by isoquercetin in vitro (2.5 ± 0.4 μM). Platelet-dependent thrombin generation decreased by 51% in the healthy volunteers compared with baseline (P = 0.0004) and by 64% in the anti-phospholipid antibody cohort (P = 0.015) following isoquercetin ingestion. To understand how PDI affects thrombin generation, we evaluated substrates of PDI identified using an unbiased mechanistic-based substrate trapping approach. These studies identified platelet factor V as a PDI substrate. Isoquercetin blocked both platelet factor Va and thrombin generation with an IC50 of ~5 μM. Inhibition of PDI by isoquercetin ingestion resulted in a 53% decrease in the generation of platelet factor Va (P = 0.001). Isoquercetin-mediated inhibition was reversed with addition of exogenous factor Va. CONCLUSION: These studies show that oral administration of isoquercetin inhibits PDI activity in plasma and diminishes platelet-dependent thrombin generation predominantly by blocking the generation of platelet factor Va. These pharmacodynamic and mechanistic observations represent an important step in the development of a novel class of antithrombotic agents targeting PDI. TRIAL REGISTRATION: Clinicaltrials.gov (NCT01722669) FUNDING: National Heart, Lung, and Blood Institute (U54 HL112302) and Quercegen Pharma.
Authors: C P Hayward; E Furmaniak-Kazmierczak; A M Cieutat; J C Moore; D F Bainton; M E Nesheim; J G Kelton; G Côté Journal: J Biol Chem Date: 1995-08-18 Impact factor: 5.157
Authors: P C Hollman; J M van Trijp; M N Buysman; M S van der Gaag; M J Mengelers; J H de Vries; M B Katan Journal: FEBS Lett Date: 1997-11-24 Impact factor: 4.124
Authors: Jasimuddin Ahamed; Henri H Versteeg; Marjolein Kerver; Vivien M Chen; Barbara M Mueller; Philip J Hogg; Wolfram Ruf Journal: Proc Natl Acad Sci U S A Date: 2006-09-07 Impact factor: 11.205
Authors: Judith Lahav; Eveline M Wijnen; Oded Hess; Samir W Hamaia; Delia Griffiths; Michael Makris; C Graham Knight; David W Essex; Richard W Farndale Journal: Blood Date: 2003-06-05 Impact factor: 22.113
Authors: Yves Balmer; Antonius Koller; Gregorio del Val; Wanda Manieri; Peter Schürmann; Bob B Buchanan Journal: Proc Natl Acad Sci U S A Date: 2002-12-30 Impact factor: 11.205
Authors: Jeffrey I Zwicker; Benjamin L Schlechter; Jack D Stopa; Howard A Liebman; Anita Aggarwal; Maneka Puligandla; Thomas Caughey; Kenneth A Bauer; Nancy Kuemmerle; Ellice Wong; Ted Wun; Marilyn McLaughlin; Manuel Hidalgo; Donna Neuberg; Bruce Furie; Robert Flaumenhaft Journal: JCI Insight Date: 2019-02-21
Authors: Junsong Zhou; Yi Wu; Fengwu Chen; Lu Wang; Lubica Rauova; Vincent M Hayes; Mortimer Poncz; Hong Li; Tong Liu; Junling Liu; David W Essex Journal: Blood Date: 2017-06-02 Impact factor: 22.113
Authors: R H Bekendam; D Iyu; F Passam; J D Stopa; K De Ceunynck; O Muse; P K Bendapudi; C L Garnier; S Gopal; L Crescence; J Chiu; B Furie; L Panicot-Dubois; P J Hogg; C Dubois; R Flaumenhaft Journal: J Thromb Haemost Date: 2018-10-12 Impact factor: 5.824